Glucagon-like peptide-2 analogues for Crohn's disease patients with short bowel syndrome and intestinal failure

Abstract

Short bowel syndrome (SBS) with intestinal failure (IF) is a rare but severe complication of Crohn's disease (CD), which is the most frequent benign condition that leads to SBS after repeated surgical resections, even in the era of biologics and small molecules. Glucagon-like peptide-2 analogues have been deeply studied recently for the treatment of SBS-IF. These drugs have a significant intestinotrophic effect and the potential to reduce the chronic dependence of SBS-IF patients on parenteral support or nutrition. Teduglutide has been approved for the treatment of SBS-IF, and apraglutide is currently in clinical development. The use of these drugs was examined with a focus on their use in CD patients.

Keywords: Apraglutide; Crohn’s disease; Glepaglutide; Glucagon-like peptide-2 analogues; Intestinal failure; Short bowel syndrome; Teduglutide.